Literature DB >> 20697257

Clostridium difficile infection.

Latisha Heinlen1, Jimmy D Ballard.   

Abstract

Clostridium difficile is the leading cause of hospital-acquired diarrhea in Europe and North America and is a serious reemerging pathogen. Recent outbreaks have led to increasing morbidity and mortality and have been associated with a new strain (BI/NAP1/027) of C difficile that produces more toxin than historic strains. With the increasing incidence of C difficile infection, clinicians have also seen a change in the epidemiology with increased infections in previously low-risk populations. This chapter highlights the current knowledge on C difficile virulence, human disease, epidemic outbreaks and optimal treatment strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20697257      PMCID: PMC2935936          DOI: 10.1097/MAJ.0b013e3181e939d8

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  92 in total

1.  Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force.

Authors:  John M Boyce; Didier Pittet
Journal:  Infect Control Hosp Epidemiol       Date:  2002-12       Impact factor: 3.254

2.  Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Authors:  Ramsey M Dallal; Brian G Harbrecht; Arthur J Boujoukas; Carl A Sirio; Linda M Farkas; Kenneth K Lee; Richard L Simmons
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

3.  Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.

Authors:  S Johnson; M H Samore; K A Farrow; G E Killgore; F C Tenover; D Lyras; J I Rood; P DeGirolami; A L Baltch; M E Rafferty; S M Pear; D N Gerding
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

4.  Clonal dissemination of a toxin-A-negative/toxin-B-positive Clostridium difficile strain from patients with antibiotic-associated diarrhea in Poland.

Authors:  H Pituch; N van den Braak; W van Leeuwen; A van Belkum; G Martirosian; P Obuch-Woszczatyński; M Łuczak; F Meisel-Mikołajczyk
Journal:  Clin Microbiol Infect       Date:  2001-08       Impact factor: 8.067

5.  Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients.

Authors:  Xing Wang Gao; Mohamed Mubasher; Chong Yu Fang; Cheryl Reifer; Larry E Miller
Journal:  Am J Gastroenterol       Date:  2010-02-09       Impact factor: 10.864

6.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

7.  The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.

Authors:  C M Surawicz; L V McFarland; R N Greenberg; M Rubin; R Fekety; M E Mulligan; R J Garcia; S Brandmarker; K Bowen; D Borjal; G W Elmer
Journal:  Clin Infect Dis       Date:  2000-10-25       Impact factor: 9.079

8.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Authors:  Lorraine Kyne; Mary Beth Hamel; Rajashekhar Polavaram; Ciarán P Kelly
Journal:  Clin Infect Dis       Date:  2001-12-17       Impact factor: 9.079

Review 9.  Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.

Authors:  Karyn M Sullivan; Linda M Spooner
Journal:  Ann Pharmacother       Date:  2010-01-13       Impact factor: 3.154

10.  Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea.

Authors:  R Cunningham; B Dale; B Undy; N Gaunt
Journal:  J Hosp Infect       Date:  2003-07       Impact factor: 3.926

View more
  41 in total

1.  Is fidaxomicin worth the cost? An economic analysis.

Authors:  Sarah M Bartsch; Craig A Umscheid; Neil Fishman; Bruce Y Lee
Journal:  Clin Infect Dis       Date:  2013-05-23       Impact factor: 9.079

2.  Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China.

Authors:  Pengcheng Du; Bo Cao; Jing Wang; Wenge Li; Hongbing Jia; Wen Zhang; Jinxing Lu; Zhongjie Li; Hongjie Yu; Chen Chen; Ying Cheng
Journal:  J Clin Microbiol       Date:  2014-06-23       Impact factor: 5.948

3.  Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion.

Authors:  Souwelimatou Amadou Amani; Tyler Shadid; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

Review 4.  Nutrition and the gut microbiome in the elderly.

Authors:  Nuria Salazar; Lorena Valdés-Varela; Sonia González; Miguel Gueimonde; Clara G de Los Reyes-Gavilán
Journal:  Gut Microbes       Date:  2016-11-03

Review 5.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

Review 6.  Understanding the mechanisms of faecal microbiota transplantation.

Authors:  Alexander Khoruts; Michael J Sadowsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-22       Impact factor: 46.802

7.  Using a Novel Lysin To Help Control Clostridium difficile Infections.

Authors:  Qiong Wang; Chad W Euler; Aurelia Delaune; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

Review 8.  [Surface disinfection in the context of infection prevention in intensive care units].

Authors:  A Kossow; S Schaber; F Kipp
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-02-21       Impact factor: 0.840

9.  Fecal microbiota transplantation in relapsing Clostridium difficile infection.

Authors:  Faith Rohlke; Neil Stollman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

10.  A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.

Authors:  Lillian S L Ting; Jens Praestgaard; Nicole Grunenberg; Jenny C Yang; Jennifer A Leeds; Peter Pertel
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.